

Hepatobiliary and Pancreas Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

LOCOREGIONAL	FIRST LINE	SECOND LINE	THIRD LINE
<p><u>UCI 19-49</u> Cabo + Ipi/Nivo + TACE</p> <p>Coord: H. Nguyen Accrual: 23/35</p>	<p><u>UCI 22-106</u> STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab (Slot request required) Coord: H. Nguyen Accrual: 9/10</p>	<p><u>UCI 16-94</u> TATE + Nivolumab (includes gastric/GEJ)</p> <p>Coord: S. Duong Accrual: 32/40</p>	
<p><u>UCI 23-75/ROUTE 90</u> Eye90 microspheres</p> <p>Coord: M. Duron Accrual: 3/15</p>	<p><u>UCI 22-211</u> MED1572 (IgG1 mAb) ± Bev Suspended for additional cohort Coord: C. Kang Accrual: 3/8</p>	<p><u>UCI 23-215</u> AZD5851 (GPC3 Autologous CAR-T) Central testing for GPC3 and no previous GPC3 treatment Coord: J. Balanguie Suspended until at least Q1 2026</p>	
<p>ADJUVANT</p> <p><u>UCI 25-136</u> Personalized Neoantigen DNA Vaccine (GNOS-PV02) vs. Surveillance</p> <p>High-Risk HCC</p> <p>DOT approved</p>	<p><u>UCI 23-104</u> Livmoniplimab + Budigalimab Atezolizumab + Bevacizumab Tremelimumab + Durvalumab Suspended until Q4 2025 Coord: S. Duong Accrual: 3/7</p>	<p><u>UCI 25-06</u> ABBV-324 (GPC3 ADC) vs. Lenvatinib</p> <p>SIV scheduled 8/6/25</p>	
		<p><u>UCI 24-09</u> RYZ801 (GPC3 radiotherapeutic)</p> <p>Pending qualification, tentative SIV October 2025</p>	
			<p><u>UCI 25-16</u> ODM-212 (Hippo pathway)</p> <p>PRMC approved</p>



■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

SYSTEMIC + OPERATIVE

ETCTN 10608
 Gemcitabine + Cisplatin +
 Durva Neo/Adjuvant for **high-risk resectable ICC**

Reopen September 2025
 Coord: H. Nguyen
 Accrual: 2/3

UCI 23-99
 Randomize, adjuvant
 Rilvegostomig/placebo +
 capecitabine or gem/cisplatin
 after BTC resection

Coord: B. Nguyen
 Accrual: 0/8

FIRST LINE

SECOND LINE+

ETCTN-10276
 M3814 ± Avelumab +
 Hypofraction Radiation

Coord: C. Kang
 Accrual: 3/5

UCI 23-200
 AZD0901 (CLND18 ADC)
Central prescreening

Suspended until Q1 2026
 Coord: M. Duron
 Accrual: 5/10

UCI 25-137
 Nanvuranlat (LAT1 inhibitor)
 vs. Physician choice
 chemotherapy

DOT approved



BORDERLINE/ LOCALLY ADVANCED

ETCTN-10366
M3814 (Peposertib) + radiation
Coord: S. Duong
Accrual: 7/13

ETCTN-10464
Olaparib + Durvalumab + radiation
Coord: S. Duong
Accrual: 1/5

UCI 23-134
Padeliporfin Vascular targeted
photodynamic therapy
Pancreatic head/uncinate w/SMA
Coord: C. Kang
Accrual: 2/8

NRG-GI011
Dose escalated radiation
RSC review

FIRST LINE LA/METASTATIC

UCI 24-105
Pitavastatin + Gemcitabine/Nab-paclitaxel
SD after 3 months of treatment w/gem/nab-paclitaxel
PRMC approved

UCI 23-200
AZD0901 (CLND18 ADC) with
NAL-IRI or Gemcitabine
Investigator discretion
Coord: S. Duong
Accrual: 5/10

UCI 22-51
ASP2138 (CLDN18.2 BiTe) with
FOLFIRINOX
Coord: P. Yang
Accrual: 27/35

SECOND LINE

ETCTN 10522
CA4948 + gemcitabine + nab-
paclitaxel
Coord: H. Nguyen
Accrual: 3/4

Review Biomarker Based Solid Tumors Pages 6 and 7

RECURRENT

UCI 24-08
SPEDOX -6 (Protein
encapsulated doxorubicin)
KRAS Mutation
Coord: B. Nguyen
Accrual: 3/50

UCI 24-113
BMS-986482 (Treg inducer)
PRMC approved



ADJUVANT

S2104

Capecitabine + Temozolomide vs observation

Pancreatic NET Ki67 > 3%

Coord: J. Balangue
Accrual: 0/2

SECOND LINE

ETCTN 10479

Lu-177 + Sunitinib

Well or moderately differentiated PNET
Up to one line of systemic therapy not including somatostatin

Coord: H. Nguyen
Accrual: 0/3

SECOND LINE+

ETCTN 10558

Lu-177 ± Triapine

NET w/positive 68 or 64 DOTATATE on scans

Coord: H. Nguyen
Accrual: 2/3

METASTATIC DIAGNOSIS

UCI 24-138

Various Neuroendocrine including Gastroenteropancreatic NEN with DLL3 expression

PRMC approved

UCI 25-75

NET/NEC solid tumors with SST2 expression

DOT approved

Mutation based studies allowing Pancreatic, HCC, and Biliary cancers + other solid tumors

Open to Accrual

Low Accruing

Pending Activation/Suspended

CLAUDIN 18.2

UCI 22-51

ASP2138 (CLDN18.2 BiTe)

Pancreatic and Gastric/GEJ

Coord: P. Yang
Accrual: 27/35

EpCAM

UCI 23-85

BA3182 (CAB T-cell: EpCAM)

All solid tumors (central
EPCAM testing)

Coord: H. Nguyen
Accrual: 4/8

KRAS/NRAS

UCI 21-53

LY3537982 (KRAS G12C
Inhibitor)

Coord: J. Choe
Accrual: 7/12

UCI 22-87

RMC-6236 (KRAS Inhibitor)

Pancreatic KRAS WT 2L

Coord: C. Kang
Accrual: 21/25

GERMLINE MUTATIONS

ETCTN-10528

Novobiocin (POLθ)
Germline mutations

Coord: H. Nguyen
Accrual: 0/5

MTAP

UCI 24-197

TNG456 (PRMT5 inhibitor)

MTAP NGS/IHC local
testing

PRMC approved

TP53

UCI 25-52

Rezatapopt (p53 reactivator)

TP53 Y220C local testing

PRMC approved

GERM/SOMATIC MUTATIONS

Various solid tumors included, or have progressed on, exhausted all therapies, or not amenable to further treatment

UCI 22-26

CB-03-10 (Androgen and glucocorticoid antagonist)

All solid tumors

Coord: B. Nguyen

Accrual: 11/12

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

BLOOD COLLECTION

UCI 21-124

ctDNA collection during HBP
workup

Coord: J. Balangué
Accrual: 17/17

UCI 23-10/PRECEDE

(Blood collection for early
detection of pancreatic
cancer)

Pending budget/contract